Form 4: LeonaBio Director Acquires Stock Options

LeonaBio, Inc. director Kelly A. Romano acquired 28,000 stock options with an exercise price of $8.35, vesting over time.

Summary

• Kelly A. Romano, a Director at LeonaBio, Inc., was granted 28,000 stock options on June 23, 2026.
• The options have an exercise price of $8.35 per share.
• These options are subject to vesting conditions, with full vesting occurring on June 23, 2027, or the day before the next annual stockholder meeting after June 22, 2026, whichever comes first.
• The grant was made under the company's Outside Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard director compensation practice rather than a significant financial event or strategic shift.

Positives

• Director compensation aligns with long-term shareholder interests through stock options.
• The grant indicates continued confidence in the company's future prospects by a board member.

Risks

• The value of the stock options is subject to market fluctuations and the company's stock performance.
• Vesting conditions mean the options are not immediately exercisable, tying their benefit to continued service and company milestones.

Future Outlook

The stock options are exercisable until June 22, 2036, with vesting occurring over the next year, indicating a long-term incentive tied to the company's performance and director's continued service.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology sector to incentivize long-term commitment and align executive interests with shareholder value, especially for companies like LeonaBio that may be in development or growth phases.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Kelly A. Romano is a related party transaction, executed under the company's established compensation policy for non-employee directors.

Stakeholder Impact

• Shareholders: The issuance of options represents potential future dilution if exercised, but also aligns director incentives with long-term share price appreciation.
• Employees: No direct impact, but reflects company's approach to executive and director compensation.
• Creditors: No direct impact.

Next Steps

• The stock options will vest according to the schedule outlined in the Outside Director Compensation Policy.
• Kelly A. Romano may exercise the vested options at the specified price of $8.35 per share.

Key Dates

Keywords

stock options, director compensation, LeonaBio, LONA, SEC Form 4, insider trading, equity award